COMMUNIQUÉS West-GlobeNewswire

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

11/11/2024 - 13:30

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX [...]

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

11/11/2024 - 13:30

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

11/11/2024 - 13:30

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase [...]

Assertio Provides Response to Letter from Short-seller

11/11/2024 - 13:30

Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company Considering Taking Legal and [...]

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

11/11/2024 - 13:30

Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today [...]

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/11/2024 - 13:30

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity [...]

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

11/11/2024 - 13:30

GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective [...]

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

11/11/2024 - 14:00

Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics; PIONEER study expands the investigation [...]

Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling

11/11/2024 - 14:00

NAPLES, Fla., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. is excited to announce a major update to its Oohvie app, an innovative platform designed to support women's health. This update not only [...]

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

11/11/2024 - 14:00

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, [...]

Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs

11/11/2024 - 14:00

—Ceribell System stand s to reduce costly ICU admissions and intra-facility patient transfers— —Military veterans face elevated risks of developing seizure disorders— SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE [...]

Nexalin Technology CEO Provides Letter to Shareholders

11/11/2024 - 14:00

HOUSTON, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today released a letter to shareholders from its CEO Mark White: Dear Shareholders, I am pleased [...]

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

11/11/2024 - 14:00

Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: [...]

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

11/11/2024 - 14:00

– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – Encouraging data adds to the body of evidence supporting potential use of [...]

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

11/11/2024 - 14:00

KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the [...]

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

11/11/2024 - 14:00

Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody [...]

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

11/11/2024 - 14:00

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure [...]

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

11/11/2024 - 14:00

In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months FLORHAM PARK, N.J., Nov. [...]

STRATA Skin Sciences Announces Favorable Court Order in Complaint Against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group

11/11/2024 - 14:15

HORSHAM, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]